2016 Annual Meeting | Cerebrovascular Disease III: Acute Ischemic Stroke

Date Monday 04/18/16

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Philip B. Gorelick, MD, MPH, F�鶹��ýӳ��

Topic(s)

Learning Objectives Participants should be able to better understand diagnosis and management of acute ischemic stroke in everyday practice in relation to intravenous tPA administration; how eligibility criteria for tPA administration have changed over the years; what recent guidelines recommend; how time to administration of tPA is being reduced by pre-hospital and other system changes; proper application of neurothrombectomy in everyday practice; and new guidelines for application of neurothrombectomy.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Other, Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic

Event Timeline
03:30 PM - 04:15 PM		tPA Administration for Acute Ischemic Stroke: A 20-Year Perspective James C. Grotta, MD, F�鶹��ýӳ��
04:15 PM - 04:30 PM		Questions and Answers James C. Grotta, MD, F�鶹��ýӳ��
04:30 PM - 05:15 PM		Neurothrombectomy for Acute Ischemic Stroke Andrew M. Demchuk, MD
05:15 PM - 05:30 PM		Questions and Answers Andrew M. Demchuk, MD

Faculty Disclosures
Philip B. Gorelick, MD, MPH, F�鶹��ýӳ��	Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AMGEN. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. Dr. Gorelick has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Thorek Memorial Hospital. Dr. Gorelick has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Thorek Memorial Hospital.
Andrew M. Demchuk, MD	Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lumosa. Dr. Demchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pfizer/BMS. Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boehringer Ingelheim. Dr. Demchuk has received stock or an ownership interest from Circle NVI. Dr. Demchuk has received intellectual property interests from a discovery or technology relating to health care.
James C. Grotta, MD, F�鶹��ýӳ��	Dr. Grotta has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Frazer Ltd. Dr. Grotta has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Haemonetics. Dr. Grotta has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acticor. Dr. Grotta has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prolong Pharma. Dr. Grotta has received publishing royalties from a publication relating to health care. Dr. Grotta has received publishing royalties from a publication relating to health care.